Why can’t the U.S. control prescription drug pricing as they do in the U.K., where per-capita spending is less than half our level?
In a capitalist democracy, many parties — the drug companies, medical associations, consumer groups — get to lobby their points of view. Is the problem intractable, or just an exercise in chaos?
Our three guests have written a book about the problem, “The Right Price: A value-based prescription for drug costs.” And although they don’t have a definitive answer, they do offer recommendations, interesting observations, and a way forward.
Featuring articles on deaths due to e-cigarette– or vaping-associated lung injury, apixaban for venous thromboembolism in cancer, the management of coronary disease in patients with advanced kidney disease, health-status outcomes in the ISCHEMIA-CKD trial, and ten weeks to crush the curve. 
Cardiovascular consults are way down. Is the threat of COVID-19 infection scaring people away from ED’s?
Though U.S. legislation targeting the problem of surprise medical bills advanced out of key congressional committees in 2019 with support from leaders in both parties, Congress ultimately failed to pass a law to end such bills.
Boomers Daily 